STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). Reblozyl demonstrated superior efficacy and durability compared to ESAs and is under review with the European Commission, with priority review approval by the United States Food and Drug Administration for the treatment of anemia in ESA-naïve adult patients with very low- to intermediate-risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced positive results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer. The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, meeting the primary endpoint. The safety profile was manageable with no new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
clinical trial
-
News
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
Rhea-AI Summary
Bristol Myers Squibb (BMY) authorizes an additional $3 billion share repurchase, bringing the total outstanding authorization to approximately $5 billion. The program allows management to execute repurchases at their discretion, based on market conditions and other considerations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
buyback
News
Bristol Myers Squibb Announces Dividend Increase
Rhea-AI Summary
Bristol Myers Squibb (BMY) has declared a quarterly dividend of $0.60 per share on its common stock, representing a 5.3% increase over last year's rate. The annual dividend rate for the fiscal year 2024 is $2.40 per share. This marks the 15th consecutive year of dividend increases and the 92nd consecutive year of paying dividends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
dividends
-
News
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
Rhea-AI Summary
Bristol Myers Squibb (BMY) has announced that the FDA has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. The FDA granted the application Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) partners with Bristol Myers Squibb (BMY) in a global licensing and research collaboration focused on cardiovascular targets. Avidity will receive $100 million upfront with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties. AOCs, Avidity's proprietary RNA therapeutics, will be utilized in the collaboration, expanding the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
News
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) will review data for the sBLA for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on Phase 3 KarMMa-3 study. The ODAC meeting date is pending, and the PDUFA target action date has been extended. The companies await the FDA's decision and anticipate the ODAC to review data related to the secondary endpoint of overall survival (OS). The KarMMa-3 study showed significant improvement in progression-free survival (PFS) and a consistent safety profile of Abecma. Final PFS and interim OS data will be presented at the 2023 ASH Annual Meeting. Regulatory applications for Abecma in earlier lines of therapy are under review in Japan, Europe, and Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
-
News
How Is BMS Making Progress on Its Renewable Energy Goals?
Rhea-AI Summary
BMS: Vice President of Sustainability Addresses Key Questions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) - FDA Approves Augtyro™ (repotrectinib) for ROS1-Positive Non-Small Cell Lung Cancer Treatment - Bristol Myers Squibb announced the FDA approval of Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Administered as an oral therapy, Augtyro is a tyrosine kinase inhibitor targeting ROS1 oncogenic fusions. The approval is based on the TRIDENT-1 study, showing a high objective response rate and durable response. Augtyro adds to Bristol Myers Squibb’s precision medicine portfolio, expanding the company’s presence in the NSCLC market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
fda approval
News
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#130 Ranked by Market Cap
#4058 Ranked by Stock Gains
#580 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.